2 enrolling by invitation. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Enrolling by invitation 2 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
Angioedemas, Hereditary (1) · Chronic Inducible Urticaria (1) · Chronic Urticaria (1) · Hereditary Angioedema Type III (1) · Hereditary Angioedema Types I and II (1)
Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2) · Skin and Connective Tissue Diseases (2) · Angioedema (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Hereditary Complement Deficiency Diseases (1) · Immunologic Deficiency Syndromes (1)
Histamine H1 Antagonists, Non-Sedating (1) · apremilast (1)
Pharvaris Netherlands B.V. (1) · Rashid Latif Medical College (1)
Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1)
2023 (1)